S6 Kinase
特异性亚型抑制剂
S6 Kinase产品
目录号 | 产品描述 | 文献引用 | 实验数据 |
---|---|---|---|
S1014 |
Bosutinib (SKI-606)Bosutinib (SKI-606) 是一种新型的双重Src/Abl抑制剂,在无细胞试验中IC50分别为1.2 nM 和 1 nM。Bosutinib也可通过阻滞p-ERK、p-S6和p-STAT3的磷酸化来有效地降低PI3K/AKT/mTOR、MAPK/ERK和JAK/STAT3信号通路的活性。Bosutinib可促进自噬。 |
![]() ![]() A,IC50 of Bosutinib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. The effect of inhibitors is presented as the percentage of ANDV-induced permeability of inhibitor-treated monolayers 3 days postinfection and 30 min post-VEGF and FITC-dextran addition. B, VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined as described for Fig. 1 at indicated times in the presence or absence of Bosutinib . |
|
S2843 |
BI-D1870BI-D1870是一种ATP-竞争性S6 ribosome抑制剂,在无细胞试验中作用于RSK1/2/3/K4,IC50分别为31 nM/24 nM/18 nM/15 nM,作用于RSK比作用于MST2,GSK-3β,MARK3,CK1和Aurora B选择性高10到100倍。BI-D1870 显示除了抗癌的属性包括活性氧的生成、提高内质网应激反应和诱导自噬。 |
![]() ![]() Expressions of active forms of all p90RSK isoforms were assessed by immunoblotting in Control vs. GR cells following treatment with increasing concentrations of BI-D1870 for 24 hours. Actin was included as a loading control.
|
|
S1558 |
AT7867AT7867是一种有效的,ATP竞争性的Akt1/2/3和p70S6K/PKA抑制剂,无细胞试验中IC50分别为32 nM/17 n/47 nM和85 nM/20 nM,对AGC激酶家族以外几乎没有抑制活性。 |
![]() ![]() UMUC-6 cells were treated with the indicated concentrations of AT7867 for 72 hours. Relative cytotoxicity compared to untreated control cells was assessed by alamarBlue. Each data points represents the mean of three independent experiments and the error bars represent the standard error of the mean. |
|
S2163 |
PF-4708671PF-4708671是一种细胞渗透性p70 ribosomal S6 kinase(S6K1亚型)抑制剂,在无细胞试验中Ki/IC50为20 nM/160 nM,作用于S6K1比作用于S6K2选择性高400倍,作用于S6K1比作用于MSK1和RSK1/2选择性分别高4和20倍以上,是第一个报道的S6K1特异性抑制剂。 |
![]() ![]() After treated with PF-4708671 (PF, 10 uM) and 4EGI-1 (50 uM) for 48 h, GRP78 and ATF4 in QBC939, RBE and HCCC-9810 cells were analyzed using western blot.
|
|
S1582 |
H 89 2HClH 89 2HCl是一种有效的PKA抑制剂,无细胞试验中Ki为48 nM,作用于PKA比作用于PKG选择性高10倍,比作用于PKC,MLCK,钙调蛋白激酶II和酪蛋白激I/II选择性高500倍。H 89 2HCl可诱导自噬。 |
![]() ![]() The effects of H89 on bTSH-induced FASN downregulation in 3T3-L1 adipocytes. Differentiated 3T3-L1 adipocytes were pretreated with either 20 µmol/L H89 or vehicle for 1 h, then treated with 0.2 µM bTSH for 8 h. Levels of FASN, pCREB, pERK1/2 and pJNK were determined by Western blotting.
|
|
S0385New |
S6K-18S6K-18 是一种高度选择性的 ribosomal protein S6 kinase beta-1 (S6K1, p70S6K, p70-S6K) 的抑制剂。 |
||
S1421 |
StaurosporineStaurosporine (CGP 41251, Antibiotic AM-2282, STS, AM-2282)是一种有效的PKC抑制剂,在无细胞试验中作用于PKCα,PKCγ 和PKCη,IC50分别为2 nM,5 nM 和 4 nM,对PKCδ(20 nM)和PKCε(73 nM作用较弱,对PKCζ (1086 nM)的活性很低。同时 对其他的激酶PKA, PKG, S6K, CaMKII, 等也显示抑制活性。Phase 3。 |
![]() ![]() |
|
S3940 |
3'-Hydroxypterostilbene3'-Hydroxypterostilbene (3'-HPT)是苦马豆和紫檀木心中的活性成分之一,可能对治疗不同类型的恶性血液肿瘤有效。3'-Hydroxypterostilbene 可通过诱导凋亡和自噬,从而有效地抑制人结肠癌细胞的生长,对COLO 205,HCT-116和HT-29 cells的IC50值分别为9.0 µM、40.2 µM和70.9 µM。3'-Hydroxypterostilbene 会抑制 PI3K/Akt/mTOR 信号通路中的p70S6K 和 p38MAPK信号通路,而激活ERK1/2, JNK1/2 信号通路。 |
||
S7704 |
LY2584702 TosylateLY2584702 Tosylate是一种选择性的,ATP竞争性p70S6K抑制剂,IC50为 4 nM。Phase 1。 |
![]() ![]() Samples were processed and analyzed for S6 and phospho-S6 content as described in methods.
|
|
S8518 |
AD80AD80,一种多激酶抑制剂,对人源RET (c-RET)、BRAF、S6K和SRC活性较强,但对mTOR的活性比AD57或AD58弱。其对RET (c-RET)的IC50值为4 nM。 |
||
S7871 |
LJI308LJI308是一种有效的,泛-RSK (p90核糖体S6激酶)抑制剂,对RSK1,RSK2,和 RSK3的 IC50 分别为 6 nM,4 nM 和 13 nM。 |
||
S7870 |
LJH685LJH685是一种高效的RSK抑制剂,其对RSK1, RSK2和RSK3的IC50分别为6 nM, 5 nM和4 nM。 |
![]() ![]() In (E), single (left panel) and double resistant (right panel) SKMel28 cells were treated with vemurafenib, the RSK inhibitor LJH-685 or the combination.
|
|
S7752 |
Pluripotin (SC1)Pluripotin (SC1)是ERK1和RasGAP的双重抑制剂,Kd值分别为98 nM和212 nM。可用来维持胚胎干细胞的自我更新。Pluripotin 还可抑制 RSK1、RSK2、RSK3 和 RSK4,对应的IC50值分别为0.5 µM、2.5 µM、3.3 µM 和 10.0 µM。 |
||
S7563 |
AT13148AT13148是一种口服的,ATP竞争性的,多AGC kinase抑制剂,对Akt1/2/3,p70S6K,PKA,和ROCKI/II的IC50分别为38 nM/402 nM/50 nM,8 nM,3 nM,和6 nM/4 nM。Phase 1。 |
![]() ![]() AT13148 exerts cytotoxic and anti-proliferative activity against human gastric cancer cells. Human gastric cancer cells (HGC-27, AGS, SNU-601, N87 and MKN-28 lines) or GEC-1 gastric epithelial cells were treated with applied concentration of AT13148 for indicated time, cell survival (A and E), cell proliferation (B and F), cell cycle distribution (C, for HGC-27 cells) and cell death (D, for HGC-27 cells) were tested by the described assays, separately. Data were presented as mean ± SD. “Ctrl” stands for untreated control cells (For all figures). “hr/hrs” stands for hour/hours (For all figures). Experiments in this figure were repeated for five times. *p < 0.05 vs. “Ctrl” group.
|
|
S7698 |
LY2584702LY2584702是一种选择性的,ATP竞争性的p70S6K抑制剂,IC50为4 nM。Phase 1。 |
![]() ![]() Murine DCs were pretreated with PBS or kinase inhibitors (10 μmol/l) wortmanni LY2584702 2 h prior to nicotine (10−7 mol/l) 12~15 h stimulation. MR expression was determined via western blot analyses (C, F). β-actin was used as an internal control.
|
目录号 | 产品描述 | 文献引用 | 实验数据 |
---|---|---|---|
S1014 |
Bosutinib (SKI-606)Bosutinib (SKI-606) 是一种新型的双重Src/Abl抑制剂,在无细胞试验中IC50分别为1.2 nM 和 1 nM。Bosutinib也可通过阻滞p-ERK、p-S6和p-STAT3的磷酸化来有效地降低PI3K/AKT/mTOR、MAPK/ERK和JAK/STAT3信号通路的活性。Bosutinib可促进自噬。 |
![]() ![]() A,IC50 of Bosutinib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. The effect of inhibitors is presented as the percentage of ANDV-induced permeability of inhibitor-treated monolayers 3 days postinfection and 30 min post-VEGF and FITC-dextran addition. B, VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined as described for Fig. 1 at indicated times in the presence or absence of Bosutinib . |
|
S2843 |
BI-D1870BI-D1870是一种ATP-竞争性S6 ribosome抑制剂,在无细胞试验中作用于RSK1/2/3/K4,IC50分别为31 nM/24 nM/18 nM/15 nM,作用于RSK比作用于MST2,GSK-3β,MARK3,CK1和Aurora B选择性高10到100倍。BI-D1870 显示除了抗癌的属性包括活性氧的生成、提高内质网应激反应和诱导自噬。 |
![]() ![]() Expressions of active forms of all p90RSK isoforms were assessed by immunoblotting in Control vs. GR cells following treatment with increasing concentrations of BI-D1870 for 24 hours. Actin was included as a loading control.
|
|
S1558 |
AT7867AT7867是一种有效的,ATP竞争性的Akt1/2/3和p70S6K/PKA抑制剂,无细胞试验中IC50分别为32 nM/17 n/47 nM和85 nM/20 nM,对AGC激酶家族以外几乎没有抑制活性。 |
![]() ![]() UMUC-6 cells were treated with the indicated concentrations of AT7867 for 72 hours. Relative cytotoxicity compared to untreated control cells was assessed by alamarBlue. Each data points represents the mean of three independent experiments and the error bars represent the standard error of the mean. |
|
S2163 |
PF-4708671PF-4708671是一种细胞渗透性p70 ribosomal S6 kinase(S6K1亚型)抑制剂,在无细胞试验中Ki/IC50为20 nM/160 nM,作用于S6K1比作用于S6K2选择性高400倍,作用于S6K1比作用于MSK1和RSK1/2选择性分别高4和20倍以上,是第一个报道的S6K1特异性抑制剂。 |
![]() ![]() After treated with PF-4708671 (PF, 10 uM) and 4EGI-1 (50 uM) for 48 h, GRP78 and ATF4 in QBC939, RBE and HCCC-9810 cells were analyzed using western blot.
|
|
S1582 |
H 89 2HClH 89 2HCl是一种有效的PKA抑制剂,无细胞试验中Ki为48 nM,作用于PKA比作用于PKG选择性高10倍,比作用于PKC,MLCK,钙调蛋白激酶II和酪蛋白激I/II选择性高500倍。H 89 2HCl可诱导自噬。 |
![]() ![]() The effects of H89 on bTSH-induced FASN downregulation in 3T3-L1 adipocytes. Differentiated 3T3-L1 adipocytes were pretreated with either 20 µmol/L H89 or vehicle for 1 h, then treated with 0.2 µM bTSH for 8 h. Levels of FASN, pCREB, pERK1/2 and pJNK were determined by Western blotting.
|
|
S0385New |
S6K-18S6K-18 是一种高度选择性的 ribosomal protein S6 kinase beta-1 (S6K1, p70S6K, p70-S6K) 的抑制剂。 |
||
S1421 |
StaurosporineStaurosporine (CGP 41251, Antibiotic AM-2282, STS, AM-2282)是一种有效的PKC抑制剂,在无细胞试验中作用于PKCα,PKCγ 和PKCη,IC50分别为2 nM,5 nM 和 4 nM,对PKCδ(20 nM)和PKCε(73 nM作用较弱,对PKCζ (1086 nM)的活性很低。同时 对其他的激酶PKA, PKG, S6K, CaMKII, 等也显示抑制活性。Phase 3。 |
![]() ![]() |
|
S3940 |
3'-Hydroxypterostilbene3'-Hydroxypterostilbene (3'-HPT)是苦马豆和紫檀木心中的活性成分之一,可能对治疗不同类型的恶性血液肿瘤有效。3'-Hydroxypterostilbene 可通过诱导凋亡和自噬,从而有效地抑制人结肠癌细胞的生长,对COLO 205,HCT-116和HT-29 cells的IC50值分别为9.0 µM、40.2 µM和70.9 µM。3'-Hydroxypterostilbene 会抑制 PI3K/Akt/mTOR 信号通路中的p70S6K 和 p38MAPK信号通路,而激活ERK1/2, JNK1/2 信号通路。 |
||
S7704 |
LY2584702 TosylateLY2584702 Tosylate是一种选择性的,ATP竞争性p70S6K抑制剂,IC50为 4 nM。Phase 1。 |
![]() ![]() Samples were processed and analyzed for S6 and phospho-S6 content as described in methods.
|
|
S8518 |
AD80AD80,一种多激酶抑制剂,对人源RET (c-RET)、BRAF、S6K和SRC活性较强,但对mTOR的活性比AD57或AD58弱。其对RET (c-RET)的IC50值为4 nM。 |
||
S7871 |
LJI308LJI308是一种有效的,泛-RSK (p90核糖体S6激酶)抑制剂,对RSK1,RSK2,和 RSK3的 IC50 分别为 6 nM,4 nM 和 13 nM。 |
||
S7870 |
LJH685LJH685是一种高效的RSK抑制剂,其对RSK1, RSK2和RSK3的IC50分别为6 nM, 5 nM和4 nM。 |
![]() ![]() In (E), single (left panel) and double resistant (right panel) SKMel28 cells were treated with vemurafenib, the RSK inhibitor LJH-685 or the combination.
|
|
S7752 |
Pluripotin (SC1)Pluripotin (SC1)是ERK1和RasGAP的双重抑制剂,Kd值分别为98 nM和212 nM。可用来维持胚胎干细胞的自我更新。Pluripotin 还可抑制 RSK1、RSK2、RSK3 和 RSK4,对应的IC50值分别为0.5 µM、2.5 µM、3.3 µM 和 10.0 µM。 |
||
S7563 |
AT13148AT13148是一种口服的,ATP竞争性的,多AGC kinase抑制剂,对Akt1/2/3,p70S6K,PKA,和ROCKI/II的IC50分别为38 nM/402 nM/50 nM,8 nM,3 nM,和6 nM/4 nM。Phase 1。 |
![]() ![]() AT13148 exerts cytotoxic and anti-proliferative activity against human gastric cancer cells. Human gastric cancer cells (HGC-27, AGS, SNU-601, N87 and MKN-28 lines) or GEC-1 gastric epithelial cells were treated with applied concentration of AT13148 for indicated time, cell survival (A and E), cell proliferation (B and F), cell cycle distribution (C, for HGC-27 cells) and cell death (D, for HGC-27 cells) were tested by the described assays, separately. Data were presented as mean ± SD. “Ctrl” stands for untreated control cells (For all figures). “hr/hrs” stands for hour/hours (For all figures). Experiments in this figure were repeated for five times. *p < 0.05 vs. “Ctrl” group.
|
|
S7698 |
LY2584702LY2584702是一种选择性的,ATP竞争性的p70S6K抑制剂,IC50为4 nM。Phase 1。 |
![]() ![]() Murine DCs were pretreated with PBS or kinase inhibitors (10 μmol/l) wortmanni LY2584702 2 h prior to nicotine (10−7 mol/l) 12~15 h stimulation. MR expression was determined via western blot analyses (C, F). β-actin was used as an internal control.
|